GleamWall
中文EN

BHIC BioScience Health Innovations, Inc.

Services-Computer Processing & Data Preparation · OTC · SEC CIK 1784440 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.4%
TTM net income YoY-190.2%
TTM EPS YoY-187.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin54.4%
Operating margin-17.4%
Net margin-18.4%
FCF margin—
EBITDA margin—

Returns

ROE-34.5%
ROA-30.3%
ROIC (approx.)-66.0%
Asset turnover1.64x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.69x
Accruals ratio20.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$970,071$1.04M$750,946$1.57M$1.13M$1.76M$1.23M$610,222
Cost of revenue$332,507$376,881$265,350$1.00M$433,196$682,985$330,925$271,213
Gross profit$637,564$659,483$485,596$571,863$698,231$1.07M$896,145$339,009
R&D expense$59,541$70,584$49,722$94,981$19,589$9,243$37,540-$3,900
SG&A expense$720,121$804,136$625,809$656,204$576,656$540,074$433,561$300,174
Operating income-$148,260-$217,882-$229,907-$156,669-$8,782$457,704$426,798$9,957
Interest expense$965———$0———
Income tax$0-$32,129—$76,961$0$0—$0
Net income-$149,225-$185,753-$229,907-$233,630-$8,782$457,704$426,798$9,957
EPS (basic)-0.01-0.02-0.02—0.000.040.01—
EPS (diluted)-0.01-0.02-0.02—0.000.040.01—
Weighted avg. shares (diluted)11.84M11.68M11.38M—10.98M11.40M44.34M—
Balance sheet
Cash & equivalents$1.69M$712,378$1.15M$661,925$1.14M$1.30M$1.03M$662,517
Receivables$478,083$396,899$78,278$399,257$63,212$390,013$93,449$100,285
Inventory$711,269$797,183$874,340$336,348$757,500$248,519$215,696$58,319
Current assets$3.01M$1.99M$2.19M$1.56M$1.99M$1.99M$1.34M$847,751
Intangibles$170,307$109,845$82,887$82,887$72,101$72,101$56,037$26,037
Total assets$3.20M$2.14M$2.33M$1.71M$2.07M$2.06M$1.39M$873,788
Total liabilities$281,516$301,209$645,749$229,851$356,140$337,632$132,921$38,548
Shareholders' equity$2.92M$1.83M$1.68M$1.48M$1.71M$1.72M$1.26M$835,240
Shares outstanding12.03M11.75M10.98M10.98M10.98M43.92M43.92M10.98M
Cash flow statement
Operating cash flow-$150,826-$541,874-$552,107-$100,696-$340,445$285,010$328,309-$50,305
Investing cash flow-$60,462-$26,958$0-$10,786$0-$16,064-$30,000-$19,000
Financing cash flow$1.19M$136,205$1.04M-$366,016$180,461$2,119$67,516$398,602

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.